Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific MeetingGlobeNewsWire • 06/04/26
Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent LitigationGlobeNewsWire • 06/03/26
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness MonthGlobeNewsWire • 06/01/26
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual MeetingGlobeNewsWire • 05/26/26
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer's Agitation LaunchMarketBeat • 05/12/26
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be DeniedSeeking Alpha • 05/04/26
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue EstimatesZacks Investment Research • 05/04/26
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/26
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease TranscriptSeeking Alpha • 05/01/26
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought LeaderGlobeNewsWire • 05/01/26
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer's DiseaseGlobeNewsWire • 04/30/26
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From NowThe Motley Fool • 03/25/26